Home › Funds › Sanofi › ANIX

Sanofi position in ANIX

Korsana Biosciences · Health Care

Sanofi reported holding 1,994,011 shares of ANIX (Korsana Biosciences) in its Q3 2026 13F filing — a position valued at US$63.8M, representing 10.13% of its reported portfolio and ranking #4 among its reported holdings. Sanofi first reported this position in Q3 2026.

Latest position (Q3 2026)1.99M sh
Reported value held$63.81M
Portfolio Weight10.13%
First reportedQ3 2026
Last changeNew
Updated2026-11-05

Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR

How Sanofi's ANIX position evolved

Sanofi first disclosed a stake in ANIX in Q3 2026 at 1,994,011 shares (US$63.8M).

Quarter by quarter

QuarterSharesValueChange
Q3 2026 1.99M $63.81M New

About ANIX and 13F data

ANIX (Korsana Biosciences) is a Health Care company. 28 other funds we track also report a position in ANIX. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ANIX

No other tracked fund reports a position in ANIX.

All ANIX fund holders →

FAQ

How long has Sanofi held ANIX?

Sanofi has disclosed ANIX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Sanofi's current position in ANIX?

As of Q3 2026, Sanofi holds 1.99M shares of ANIX (Korsana Biosciences), valued at $63.81M, representing 10.13% of its reported portfolio and ranking #4.

Has Sanofi been buying or selling ANIX?

In the latest 13F filing (Q3 2026), Sanofi newly opened its position in ANIX.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.